BWA
BMRN icon

Basecamp Wealth Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Basecamp Wealth Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.84K Sell
172
-64
-27% -$3.51K ﹤0.01% 1011
2026
Q1 		$13.3K Buy
236
+160
+211% +$9.33K ﹤0.01% 938
2025
Q4 		$4.52K Buy
+76
New +$4.14K ﹤0.01% 1169

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Basecamp Wealth Advisors's BMRN Position: Q2 2026 in Review

Basecamp Wealth Advisors reduced its BioMarin Pharmaceuticals (BMRN) stake by 27% in Q2 2026, selling an estimated $3.51K and leaving 172 shares worth $9.84K. The position accounts for ﹤0.01% of the portfolio, ranked #1011.

Basecamp Wealth Advisors first reported a position in BMRN in Q4 2025 and has held it in 3 quarters since. The position peaked at $13.3K in Q1 2026. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Basecamp Wealth Advisors held 172 shares of BioMarin Pharmaceuticals worth $9.84K as of Q2 2026.
  • Basecamp Wealth Advisors sold 64 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $3.51K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1011 holding.
  • Basecamp Wealth Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Basecamp Wealth Advisors's BioMarin Pharmaceuticals position peaked at $13.3K in Q1 2026.
  • 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.